Internal Med

Your Article Summary

See Latest Articles

Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials
Annals of Oncology, 11/04/09

Tang PA et al. – INV overestimate RR compared with IRC. Given the variability in assessing RR and PFS between INV and IRC, an IRC should be considered if the primary end point is on the basis of assessments of changes in tumor lesions.

• Phase III trials reporting INV and IRC assessments identified
• Difference in end point assessment (IRC – INV) across all study arms determined
• Random-effects model used to calculate mean difference between INV and IRC RR as well as PFS
• Differences in estimated benefits of treatment (experimental – control) between IRC and INV determined

• Twenty-one trials included (18 RR, 8 PFS)
• Estimated mean difference between IRC- and INV-determined RR 4.57% [95% confidence interval (CI) 2.95% to 6.19%].
• For median PFS, estimated mean difference was –0.19 (95% CI –0.68 to 0.29) months
• Difference in estimated benefits of treatment ranged from –7.0% to 7.2% for RR and –2.0 to +2.4 months for PFS; no evidence of systemic bias by INV (P = 0.54 for RR and 0.31 for PFS)

Today in Epidemiology...keeping you current

Receive free subspecialty "5-minute updates" via email

Comparative study of control selection in a national population -based case-control study: Estimating risk of smoking on cancer deaths in Chinese men
International Journal of Medical Sciences , 11/25/09

Effect of Laropiprant, a PGD2 Receptor 1 Antagonist, on Estradiol and Norgestimate Pharmacokinetics After Oral Contraceptive Administration in Women
American Journal of Therapeutics, 11/25/09

Increased Prevalence of Metabolic Syndrome in Individuals with Osteoarthritis: An Analysis of NHANES III Data
Postgraduate Medicine, 11/24/09

 See all of Epidemiology